Why Biotech Initiatives Fall Short
The science is
rarely the issue
After 40+ years of combined experience in drug development, and an ongoing interview series with senior leaders across dozens of biotech organizations, five recurring patterns emerge as the primary drivers of program delays and failures. None of them are scientific.
"Truth-seeking behaviours to understand disease biology can be over-ridden by progression-driven behaviours that reward scientists for meeting numerical volume-based goals."
The five recurring patterns
Where organizations lose momentum
These patterns emerge in different combinations and intensities depending on stage and context - but they almost never appear alone. Organizations typically experience several simultaneously.
Leading a drug development organization is genuinely difficult. The pace, the scientific complexity, and the pressure of investor timelines create conditions where important signals - about program risk, team dynamics, or strategic misalignment - can be difficult to surface and act on. When those signals do not reach decision-makers, short-term momentum can mask longer-term structural challenges.
Where this shows up
Programs advance based on optimism rather than data. Critical technical concerns are raised but do not change decisions. Teams operate with different assumptions about priorities. The gap between stated strategy and actual behavior widens over time.
Cross-functional collaboration in biotech is structurally challenging. Different disciplines have different vocabularies, different timelines, and different definitions of progress. When communication between functions is incomplete or infrequent, the result is a series of missed opportunities - for early course correction, for innovation at the boundaries of disciplines, and for the kind of integrated problem-solving that complex programs require.
Where this shows up
Circular conversations. Stakeholder management that produces presentations but not alignment. Decisions made in isolation that create problems downstream. Teams that are each individually high-performing but collectively inefficient.
Organizations rarely fail for lack of a strategy. They fail because the strategy does not translate into shared priorities, explicit tradeoffs, and clear decision criteria at every level. When the meaning of "success" is interpreted differently by the research team, the clinical team, the finance function, and the board, resource allocation becomes political rather than scientific.
Where this shows up
Diffuse effort across too many priorities. Tradeoff conversations that are avoided rather than resolved. Resource allocation that reflects internal politics more than scientific merit. Teams that are busy but not moving in the same direction.
The question of who you need, when you need them, and in what capacity is one of the most consequential and underappreciated decisions in building a biotech organization. Hiring full-time when fractional expertise would suffice burns capital and creates premature complexity. Failing to bring in the right specialized expertise at a critical transition - particularly at the research-to-clinic boundary - creates bottlenecks that are difficult and expensive to unwind.
Where this shows up
This is particularly acute at translational and clinical-entry stages - bottlenecks appear where they are hardest to diagnose, or remain invisible until it is too late. Critical capabilities absent at key inflection points. Organizational design that reflects what was needed six months ago, not what is needed now.
Growth in a biotech organization is not linear. Teams scale rapidly in response to scientific progress or fundraising milestones - and the operating systems that hold people and priorities together often cannot keep pace. The result is an organization that is structurally more complex without being operationally more capable.
Where this shows up
"Companies grow fast in complexity, but not in cohesion." - Biotech CSO. Capital burns quickly without proportional progress. New hires find it difficult to understand how their work connects to program goals. The addition of people paradoxically slows decisions rather than accelerating them.